Hormonal
Tirzepatide significantly reduces HbA1c and body weight in adults with Type 1 Diabetes (T1D) without increasing the risk of diabetic ketoacidosis (DKA) or time below range.
If you have Type 1 Diabetes and struggle with weight or high blood sugar despite insulin, ask your doctor about tirzepatide. This study shows it can lower your A1c and help you lose significant weight (over 10% in some cases) without increasing the risk of dangerous ketones or low blood sugar, provided it is managed carefully by a specialist.
Tirzepatide significantly reduced HbA1c and body weight in adults with T1D... The drug was relatively safe and well tolerated... No DKA event was reported during the 8-month follow-up.
Why this rating
Small sample size (n=26), retrospective, single-center, no control group.
Source
Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
Halis Kaan Aktürk et al. · Journal of Diabetes Science and Technology · 2024
DOI 10.1177/19322968231223991
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →